950-P: Virtual and Self-Guided Omnipod 5 Automated Insulin Delivery (AID) System Onboarding—Real-World Outcomes by Training Type
Authors: BERGET CARI , FORLENZA GREGORY P. , SHERR JENNIFER L. , DESALVO DANIEL , ALEPPO GRAZIA , WILMOT EMMA G. , HUYETT LAUREN M. , HADJIYIANNI IRENE , MENDEZ JOSE J. , CONROY LINDSEY , LY TRANG T. 
Published: June 2024

Users new to the Omnipod 5 AID System can complete training and onboarding via personalized trainer-led education, virtually or in-person, or for those upgrading from an earlier Omnipod System, online, self-guided training modules can be completed. This study aimed to evaluate outcomes by training type among people with T1D initiating the Omnipod 5 System. Continuous glucose monitoring (CGM) and insulin data from Omnipod 5 users in the US with T1D aged ≥2y and using ≥5 units of insulin per day with ≥90 days of data available in the cloud-based data management system were included. Data from 31,027 users with sufficient CGM data (≥75% of days with ≥220 readings) and using the lowest target setting (average glucose target of 110mg/dL) aged &lt;18y (n=6,774) and ≥18y (n=24,253) were available at the time of analysis. For pediatric users, 35.9% completed self-guided training and 64.1% completed trainer-led education (20.4% in-person; 43.7% virtual). In adults, trainer-led education was more common (75.1% of users: 24.6% in-person; 50.5% virtual). Glycemic outcomes and percent time in Automated Mode were similar across training types (Table). These findings from over 31,000 people using the Omnipod 5 AID System support the effectiveness of virtual and self-guided training for AID systems and support expansion of these options to facilitate convenient and timely access to AID technology.

Disclosure

C. Berget: Speaker's Bureau; Dexcom, Inc., Insulet Corporation, embecta. G.P. Forlenza: Research Support; Abbott, Dexcom, Inc. Consultant; Dexcom, Inc. Research Support; Insulet Corporation. Consultant; Insulet Corporation. Research Support; Medtronic. Advisory Panel; Medtronic. Research Support; Tandem Diabetes Care, Inc. Consultant; Tandem Diabetes Care, Inc. J.L. Sherr: Consultant; Medtronic. Advisory Panel; Medtronic, Insulet Corporation. Speaker's Bureau; Insulet Corporation. Advisory Panel; Vertex Pharmaceuticals Incorporated, MannKind Corporation, StartUp Health T1D Moonshot, Bigfoot Biomedical, Inc., Cecelia Health. Speaker's Bureau; Zealand Pharma A/S. D. DeSalvo: Advisory Panel; Insulet Corporation. Consultant; Dexcom, Inc. G. Aleppo: Consultant; Dexcom, Inc., Insulet Corporation. Research Support; Insulet Corporation. Consultant; Medscape. Research Support; MannKind Corporation, Tandem Diabetes Care, Inc., WellDoc, Fractyl Health, Inc. Consultant; Eli Lilly and Company, Bayer Inc. Research Support; Emmes. E.G. Wilmot: Other Relationship; Abbott. Speaker's Bureau; AstraZeneca. Other Relationship; Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, embecta, Medtronic, Novo Nordisk. Advisory Panel; Roche Diabetes Care. Other Relationship; Sanofi. Speaker's Bureau; Ypsomed AG. L.M. Huyett: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. I. Hadjiyianni: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. J.J. Mendez: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. L. Conroy: Employee; Insulet Corporation. Stock/Shareholder; Insulet Corporation. T.T. Ly: Employee; Insulet Corporation.

Funding

Insulet Corporation